The benefit of HER2-targeted therapy was reported in patients with HER2 expression in CTCs rather than in patients with HER2 expression in tumor tissues34,54, indicating that HER2 status on CTCs may be a promising blood marker for HER2-targeted therapy compared to that of tumor tissues. This evidence concerns the gene ERBB2 and neoplasm.